Wall Street Zen Downgrades Acurx Pharmaceuticals (NASDAQ:ACXP) to Sell

Acurx Pharmaceuticals (NASDAQ:ACXP) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other analysts have also issued reports on the company. HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Acurx Pharmaceuticals in a research note on Tuesday, September 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Acurx Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $31.00.

Acurx Pharmaceuticals Trading Down 2.8%

NASDAQ ACXP opened at $3.35 on Friday. The firm has a market capitalization of $7.01 million, a P/E ratio of -0.39 and a beta of -1.25. The firm’s fifty day moving average price is $4.87 and its two-hundred day moving average price is $6.09. Acurx Pharmaceuticals has a 1 year low of $3.17 and a 1 year high of $25.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.23) earnings per share for the quarter, topping the consensus estimate of ($1.61) by $0.38. On average, research analysts anticipate that Acurx Pharmaceuticals will post -0.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

An institutional investor recently bought a new position in Acurx Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned about 70.13% of Acurx Pharmaceuticals as of its most recent SEC filing. Institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).